Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
Adding bedaquiline or delamanid to background regimen for treatment of multi-drug resistant tuberculosis: a cost-effectiveness analysis
- At: 2017 FIP Congress in Seoul (South Korea)
- Type: Poster
- By: YOU, Joyce (The Chinese University of Hong Kong, School of Pharmacy, Shatin, Hong Kong SAR China)
- Co-author(s): Wai-Ying Yip School of Pharmacy, The Chinese University of Hong Kong, Shatin, Hong Kong
BackgroundMulti-drug resistant tuberculosis (MDR-TB) is a growing global threat, especially in the Asia region. Background regimens (BRs) for MDR-TB treatment are usually poorly tolerated with moderate success rate. Two anti-TB agents (bedaquiline and delamanid) with improved sputum conversion rates in clinical trials are recently licensed for.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019